Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
A phase 1/2 trial of Ga-68 P16-093 PET/CT scan in prostate cancer, run by Five Eleven Pharma, Inc., active and no longer recruiting.
Overview
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer is a phase 1/2 interventional study registered as NCT03444844 by Five Eleven Pharma, Inc., with 60 participants enrolled, started 2018-05-10 and due to reach its primary completion in 2020-10-27. Interventions recorded: Ga-68 P16-093 PET/CT scan.
Similar pages
not linked directly; found by shared links- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET (positron emission tomography), PET/CT, Gallium-68, Prostate cancer and the tag pipeline.
- TrialThis Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Shares PET (positron emission tomography), PET/CT, Gallium-68, Prostate cancer and the tag pipeline.
- TrialHER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Shares PET (positron emission tomography), PET/CT, Gallium-68 and the tag pipeline.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), PET/CT, Prostate cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
- AgentPSMA-1007 F-18
Shares PET (positron emission tomography), Gallium-68, Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Gallium-68, Prostate cancer and the tag pipeline.